This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...

Goldman Sachs analyst Chris Shibutani has reiterated their bullish stance on MRK stock, giving a Buy rating today. Chris Shibutani has given his Buy rating due to a combination of factors surrounding ...

In a split showing for cancer powerhouse Merck, its immunotherapy Keytruda continued a losing streak in prostate cancer but chalked up a win to pressure an industry-first approval by AstraZeneca.

Investing.com -- Formycon shares jumped more than 6% on Thursday after the company announced its first commercial agreement for FYB206, its biosimilar candidate to Merck’s Keytruda. The deal covers ...

The rapid growth and expansion of the pharmaceutical industry has changed how we treat and prevent diseases. But there are still many intractable conditions. Research and development (R&D) in these ...